secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104547
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Q2 net loss $70.1M, cash $510.9M; appoints new directors; CLN-978 enrolling
--------------------------------------------------------------------------------

- Q2 2025 net loss $70.1M vs $42.0M; R&D expenses $61.0M vs $36.3M; cash and investments $510.9M providing runway into 2028.
- Board changes effective Aug 7: Anne-Marie Martin and David Ryan resigned; Mittie Doyle and Andrew Allen appointed as Class I and II directors, respectively.
- CLN-978 Phase 1 studies in SLE, RA, and Sjögren's actively enrolling; initial SLE safety and B cell depletion data expected Q4 2025.
- Velinotamig (BCMAxCD3 T cell engager) in-licensed from Genrix Bio for $20M upfront; up to $692M in milestones plus tiered royalties.
- Partner Taiho plans to submit NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by end of 2025 based on REZILIENT1 pivotal data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025104547/0000950170-25-104547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025104547/cgem-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer